Table 2.

Patients’ characteristics

	MS (n = 217)				OND (n = 212)
	CIS	RRMS	SPMS	PPMS	Devic	Non.INF	INF
Total no. of patients	86	175	34	8	1	116	96
Female/male	63/23	127/48	22/12	4/4	1/0	79/37	64/32
Age, median (IQR)	35 (29–42)	38 (30–46)	53 (45–62)	50 (38–56)	32	44 (33–53)	52 (40–61)
EDSS, median (IQR)	1.5 (1.0–2.0)	2 (1.0–2.5)	5.5 (4.5–6.0)	4 (3.0–4.0)	2.0	n.a.	n.a.
Disease duration, years, median (IQR)	2 (1–2)	1 (1–2)	8 (2–17.3)	3 (2–7.5)	1	-	-
% sampled during relapse	22	18	n.a.	n.a.	n.a.	n.a.	n.a.
% OCB positive	68	85	81	100	100	0	8.3
CSF mononuclear cells (cells/μL), median(IQR)	3 (1–8)	5 (2–10)	3(1–5)	3(0.8–4.3)	4	1 (1–2.3)	2 (1–4)
CSF protein (g/L), median (IQR)	0.4 (0.3–0.5)	0.5 (0.4–0.6)	0.5 (0.5–0.7)	0.4 (0.4–0.6)	0.2	0.4 (0.3–0.5)	0.5 (0.4–0.6)

MS, multiple sclerosis; n, number of patients; CIS, clinically isolated syndrome suggestive of MS; RRMS, relapsing–remitting MS; SPMS, secondary progressive MS; PPMS, primary progressive MS; OND, other neurological disease; OND.INF, other neurological disease with signs of inflammation; EDSS, Expanded Disability Scale; IQR, Inter Quartile Range; OCB, oligoclonal bands; n.a., not applicable.